Last reviewed · How we verify
SHR-A1811;Albumin paclitaxel — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SHR-A1811;Albumin paclitaxel (SHR-A1811;Albumin paclitaxel) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SHR-A1811;Albumin paclitaxel TARGET | SHR-A1811;Albumin paclitaxel | Jiangsu HengRui Medicine Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SHR-A1811;Albumin paclitaxel CI watch — RSS
- SHR-A1811;Albumin paclitaxel CI watch — Atom
- SHR-A1811;Albumin paclitaxel CI watch — JSON
- SHR-A1811;Albumin paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). SHR-A1811;Albumin paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/shr-a1811-albumin-paclitaxel. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab